Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis

https://doi.org/10.1016/j.diabres.2016.06.014Get rights and content

Highlights

  • Significant reduction in FBG was noted in the probiotic group.

  • Inconsistent effects of probiotics on HbA1c, inflammation and oxidative stress.

  • Clinical studies must consider probiotic strains and study population.

Abstract

Aims

To systematically review evidence of probiotic interventions against type 2 diabetes mellitus (T2DM) and analyse the effects of probiotics on glycaemic control among T2DM patients.

Methods

Electronic search using five electronic databases was performed until October 2015. Relevant studies were identified, extracted and assessed for risk of bias. The primary outcomes of this review were glycated haemoglobin (HbA1c) and fasting blood glucose (FBG). Fasting plasma insulin, homeostasis model assessment-insulin resistance, C-reactive protein, interleukin-6 and malondialdehyde, were identified as the secondary outcomes. Mean differences (MD) between probiotics and control groups for all outcomes were pooled using either Fixed- or Random-Effect Model. Statistical heterogeneity was assessed using I2 and Chi2 tests.

Results

Six randomised controlled trials (RCTs) were included in the systematic review, whereas only five were included in meta-analysis. Most RCTs were presented with low or unclear risk of bias. When compared to placebo, FBG was significantly lower with probiotic consumption (MD = −0.98 mmol/L; 95% CI: −1.17, 0.78, p < 0.00001), with moderate but insignificant heterogeneity noted. Insignificant changes between the groups were also noted for HbA1c and other secondary outcomes.

Conclusions

A moderate hypoglycaemic effect of probiotics, with a significantly lower FBG was noted. Findings on HbA1c, anti-inflammatory and anti-oxidative effects of probiotics in the clinical setting, however, remain inconsistent. The findings imply the need for well-designed clinical studies to further assess the potential beneficial effects of probiotics in management of T2DM.

Introduction

Type 2 diabetes mellitus (T2DM), a metabolic disease characterised by hyperglycaemia, is associated with either insensitivity of insulin or lack of insulin secretion [1]. It is the leading cause of cardiovascular disorders, blindness, end-stage renal failure, amputations and hospitalisation [2]. The incidence of T2DM is increasing. In 2011, 366 million adults worldwide were estimated to suffer from diabetes mellitus. The number is projected to increase to 592 million by year 2035 [3]. In addition, the management of T2DM is costly. In 2010, the global estimation of diabetes expenditures was USD376 billion; the expenditure is predicted to increase to USD490 billion in the next 20 years [4]. Given its substantial health and socio-economic burden, identifying an optimal therapy for T2DM is important.

The underlying mechanisms of the abnormal rise of blood glucose level are complex and multi-factorial [5]. T2DM associated risk factors that have already been identified include age, genetic predisposition, sedentary lifestyle, diet patterns and stress [6]. Recently, emerging data suggested that gut microbiota may have an important role in progression and development of T2DM. It was reported that when the microbiome balance is shifted in favour of the unhealthy ones, the level of metabolic endotoxin will increase and potentially trigger a chronic, low-grade inflammation [7]. The release of inflammatory cytokines can cause oxidative stress [8], and ultimately, lead to destruction of β-cells in the pancreas. It was found that probiotic consumption could increase the amount of beneficial bacteria (i.e. Bifidobacteria) in the gut, which could in turn reduce intestinal permeability towards lipopolysaccharide (LPS) produced by unhealthy gut microorganisms, and altogether attenuate systemic inflammation responses [9]. As such, modulating gut microbiota through dietary interventions (e.g. probiotic intake) may be useful in the prevention and control of inflammatory metabolic disorders including T2DM.

Probiotics are live microorganisms that when administered in sufficient amounts can confer health benefit to their host [10]. Lactobacilli and bifidobacteria are the two most common types of probiotics [5]. The global probiotic market was estimated at USD33.19 billion in 2015 and it is projected to reach USD46.55 billion by 2020; dominated by Asia–Pacific market [11]. The applications of probiotics as alternative biotherapeutics have been successfully demonstrated in treatment of respiratory infection [12], inflammatory bowel disease [13], antibiotic associated diarrhoea [14] and ulcerative colitis [15]. In spite of the booming in vitro and in vivo probiotic studies against metabolic diseases such as T2DM, their application at clinical settings remains scarce [16], [17]. In fact, the findings from the very few clinical trials that have been conducted were inconsistent. The most recent systematic review and meta-analysis on probiotic use in glycaemic control comprised of 17 trials, involving a broad range of study populations [i.e. healthy participants, T2DM patients, patients with hypercholesterolaemia, non-alcoholic steatohepatitis or metabolic syndrome, obese populations and patients with gestational diabetes mellitus (GDM)]. The findings, however, were limited by substantial inter-study clinical heterogeneity [18]. In addition, the effects of probiotics against vital parameters like glycated haemoglobin (HbA1c), anti-inflammatory and anti-oxidative markers were not assessed [18]. This systematic review and meta-analysis focused mainly on clinical studies that have investigated the efficacy of probiotics in T2DM patients, highlighting areas that were not usually addressed by previous review (Supplementary Table 1): the effect of probiotic on HbA1c and fasting blood glucose (FBG), anti-inflammation and anti-oxidation.

Section snippets

Literature search strategy

A search of electronic databases, including EMBASE, PubMed/Medline, SpringerLink, the Cochrane Library and trial registry website (ClinicalTrials.gov) was performed. The final search was carried out in October 2015, using combinations of search terms which included ‘diabetes mellitus’, ‘probiotics’, ‘lactobacilli’, ‘bifidobacter’, ‘streptococcus’, ‘microbiota’, ‘microflora’, ‘microbiome’, ‘gut hormone’, ‘insulin sensitivity’, ‘anti-oxidant’ and ‘anti-inflammatory’. In addition, citations in

Description of included studies

Out of the 260 records that have been identified through the search (after removal of duplicates), 254 records were excluded based on the pre-specified criteria (Fig. 1). Table 1 outlines the details of all eligible studies and their findings. Whilst a total of six eligible studies that have investigated the use of probiotics in T2DM patients were included in the qualitative synthesis (systematic review) [8], [20], [21], [22], [23], [24], only five were included in quantitative synthesis

Discussion

The current meta-analysis is the first to examine the pooled estimate of probiotics on HbA1c. The use of HbA1c is a gold standard in clinical management of T2DM [25] and it permits comparability among the published studies. A 1% reduction in HbA1c has been associated with 21% risk reduction of diabetes related-end points and 37% risk reduction for microvascular complications [26]. Hence, a 1% reduction in HbA1c is considered to be clinically relevant. The findings from the current meta-analysis

Conclusion

The current meta-analysis suggested moderate beneficial hypoglycaemic effects of certain probiotics, with significantly lower FBG. Findings on HBA1c, anti-inflammatory and anti-oxidative effects of probiotics in the clinical setting, however, remain inconsistent, and thus, merits further investigations in future clinical studies. Based on the current literature, well designed, prospective clinical studies investigating the effects of probiotic administration on glycaemic control in T2DM

Declaration of interest

No competing interest declared by the authors.

Authors contribution

Each author contributed equally in this study.

Acknowledgements

The authors thank the Ministry of Education Malaysia for financial support under the Fundamental Research Grant Scheme [600-RMI/FRGS 5/3 (22/2014)].

References (49)

  • P. Zhang et al.

    Global healthcare expenditure on diabetes for 2010 and 2030

    Diabetes Res Clin Pract

    (2010)
  • Panwar et al.

    Probiotics as potential biotherapeutics in the management of type 2 diabetes-prospects and perspectives

    Diabetes Metab Res Rev

    (2013)
  • F.B. Hu et al.

    Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

    N Engl J Med

    (2001)
  • M. Mohamadshahi et al.

    Effects of probiotics yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes

    BioImpacts

    (2014)
  • B. Jayashree et al.

    Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes

    Mol Cell Biochem

    (2014)
  • S. Khani et al.

    Probiotics an alternative strategy for prevention and treatment of human disease: a review

    Inflamm Allery Drug

    (2012)
  • Markets and Markets

    Probiotic Ingredients Market by Function (Regular, Preventative, Therapy), Application (Food & Beverage, Dietary Supplements, & Animal Feed), End Use (Human & Animal Probiotics), Ingredient (Bacteria & Yeast), and by Region – Global Trends & Forecast to 2020

    (2015)
  • K. Shida et al.

    Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers

    Eur J Nutr

    (2015)
  • E.-H. Kim et al.

    High concentrated probiotics improve inflammatory bowel diseases better than commercial concentration of probiotics

    J Food Drug Anal

    (2012)
  • S. Wong et al.

    A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial

    Br J Nutr

    (2014)
  • B.R. Goldin et al.

    Clinical indications for probiotics: an overview

    Clin Infect Dis

    (2008)
  • A.C. Gomes et al.

    Gut microbiota, probiotics and diabetes

    Nutr J

    (2014)
  • B.M. Carvalho et al.

    Influence of gut microbiota on subclinical inflammation and insulin resistance

    Mediat Inflamm

    (2013)
  • Y. Ruan et al.

    Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled trials

    PLoS One

    (2015)
  • Cited by (0)

    View full text